Moreover, PGE2 inhibited RIPK3 expression while increasing the expression of nuclear factor kappa B (NFκB) and cyclooxygenase-2 (COX-2) in MDSCs, suggesting that RIPK3 and PGE2 could be therapeutic targets in CRC patients (Figure 1) [54]. Here, RIPK3 is linked to colorectal carcinoma.